10,13-dimethyl-17-prop-1-en-2-yl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 10,13-dimethyl-17-prop-1-en-2-yl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• 化学式: C₂₂H₃₄O
• 分子量: 314.5
• InChiKey: JRWLCFVPJFFOTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] C7 SUBSTITUTED OXYSTEROLS AND METHODS AS NMDA MODULATORS<br/>[FR] OXYSTÉROLS SUBSTITUÉS EN C7 ET PROCÉDÉS EN TANT QUE MODULATEURS NMDA
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2018064649A1

  公开（公告）日：2018-04-05

  Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式(A)提供化合物：以及药用可接受的盐和药物组合物；其中R1A，R1B，n，R2A，R2B，R3和R4如本文所述定义。本发明的化合物被认为可用于预防治疗各种疾病。
• [EN] OXYSTEROLS AND METHODS OF USE THEREOF<br/>[FR] OXYSTÉROLS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2018075699A1

  公开（公告）日：2018-04-26

  Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式（I）提供化合物及其药学上可接受的盐，以及药物组合物；其中R2、R3、R4、R5和R6的定义如本文所述。本发明的化合物被认为对预防和治疗各种疾病条件有用。
• Conjugated Neuroactive Steroid Compositions And Methods Of Use
  申请人：Marx Christine

  公开号：US20130245253A1

  公开（公告）日：2013-09-19

  The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of, or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject.